01 02 03 04 05
06 07 08 09 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30 31    
Add An Event

VISE 6th Annual Surgery, Intervention, and Engineering Symposium

Wednesday, December 13, 2017,

Event Image
  • Location: Light Hall • 2215 Garland Avenue • Nashville, TN 37232
  • Room: 202

keynote to be delivered by

Eben Rosenthal
Ann & John Doerr Medical Director
Stanford Cancer Center

Light Hall Room 202
4:10 p.m. – 5:10 p.m. followed by reception

Registration is OPEN! Click here.

“Leveraging Light in the OR: Finding an Optical Contrast Agent”

Over the past two decades, synergistic innovations in imaging technology have resulted in a revolution in which a range of biomedical applications are now benefiting from fluorescence imaging. Specifically, advances in fluorophore chemistry and imaging hardware, and the identification of targetable biomarkers have now positioned intraoperative fluorescence as a highly specific real-time detection modality for surgeons in oncology. In particular, the deeper tissue penetration and limited autofluorescence of near-infrared (NIR) fluorescence imaging improves the translational potential of this modality over visible-light fluorescence imaging. Rapid developments in fluorophores with improved characteristics, detection instrumentation, and targeting strategies led to the clinical testing in the early 2010s of the first targeted NIR fluorophores for intraoperative cancer detection. The foundations for the advances that underline this technology continue to be nurtured by the multidisciplinary collaboration of chemists, biologists, engineers, and clinicians. In this Review, we highlight the latest developments in NIR fluorophores, cancer-targeting strategies, and detection instrumentation for intraoperative cancer detection, and consider the unique challenges associated with their effective application in clinical settings.

Eben Rosenthal is a surgeon-scientist who serves as the John and Ann Doerr Medical Director of the Stanford Cancer Center.  He works collaboratively with the Stanford Cancer Institute and Stanford Health Care leaders to set the strategy for the clinical delivery of cancer care across Stanford Medicine and growing cancer networks.  He is a professor of Otolaryngology and Radiology (courtesy) and a member of Molecular Imaging Program at Stanford (MIPS). He continues to be clinically active as an oncologic and microvascular reconstructive surgeon.

Dr. Rosenthal has conducted multiple early phase clinical trials for diagnostic and therapeutic agents for the treatment of solid tumors. He has been NIH funded for over a decade in targeted, translational research.  He is part of a multidisciplinary team of clinical and basic scientists that have successfully performed preclinical studies, nonhuman primate IND-enabling studies, successfully performed the first in human clinical trials using fluorescently labeled antibodies as a cancer specific contrast agent for use in the operating room. Ongoing clinical trials include brain, pancreas, skin and head and neck tumors.